The advent of bruton tyrosine kinase inhibitors (BTKi) has offered more therapeutic choices for patients with B-cell malignancies. However, with its widespread application in recent years, the use of BTKi increases the risk of severe infections in patients. Here, we report three cases of B-cell malignancies, including one case of chronic lymphocytic leukemia and two cases of diffuse large B-cell lymphoma. During treatment with BTKi zanubrutinib, different degrees of invasive fungal disease (IFD) of the central nervous system occurred in these patients. All patients fully recovered following antifungal therapy. With a median follow-up of 35 months, all patients remained in a continuous remission state, and none of them had a recurrence of IFD.

Objective To determine 32 anabolic agents in tablets,capsules and injections using liquid chromatography-high resolution mass spectrometry(LC-HRMS),so as to provide technical support in the fields of anti-doping and judicial identification.Methods The tablet grinded into powder,capsule samples extracted using a methanol∶water(7∶3)solution and injection underwent centrifugation and filtration.The separation was performed on a Waters Acquity UPLC HSS T3 column(100 mm×2.1 mm,1.8 μm),followed by gradient elution using ammonium acetate(20 mmol/L)solution containing 0.1%formic acid,5%acetonitrile and acetonitrile system as mobile phases,and detection by heated electrospray ionization in positive mode with a primary full-scan/data-dependent secondary scan mode.The established analytical method was subjected to methodological validation and parameters such as se-lectivity,sensitivity,matrix effect and delay effect were investigated.Meanwhile,the method was ap-plied to the detection of anabolic agents in 20 samples of tablets,capsules and injections provided by the authorities.Results The detection limits for 32 anabolic agents ranged from 1～200 μg/mg in the powder and 1～200 ng/mL in the injection.When this method was applied to the analysis of actual samples,five anabolic agents,including methandrostenolone and stanozolol,were identified among the 20 samples,disconsistent with labels on the package.Conclusion The LC-HRMS method is simple in pretreatment,sensitive and suitable for the detection of anabolic agents in tablet,capsule and injec-tion samples in the fields of anti-doping and judicial identification.

Objective To determine 32 anabolic agents in tablets,capsules and injections using liquid chromatography-high resolution mass spectrometry(LC-HRMS),so as to provide technical support in the fields of anti-doping and judicial identification.Methods The tablet grinded into powder,capsule samples extracted using a methanol∶water(7∶3)solution and injection underwent centrifugation and filtration.The separation was performed on a Waters Acquity UPLC HSS T3 column(100 mm×2.1 mm,1.8 μm),followed by gradient elution using ammonium acetate(20 mmol/L)solution containing 0.1%formic acid,5%acetonitrile and acetonitrile system as mobile phases,and detection by heated electrospray ionization in positive mode with a primary full-scan/data-dependent secondary scan mode.The established analytical method was subjected to methodological validation and parameters such as se-lectivity,sensitivity,matrix effect and delay effect were investigated.Meanwhile,the method was ap-plied to the detection of anabolic agents in 20 samples of tablets,capsules and injections provided by the authorities.Results The detection limits for 32 anabolic agents ranged from 1～200 μg/mg in the powder and 1～200 ng/mL in the injection.When this method was applied to the analysis of actual samples,five anabolic agents,including methandrostenolone and stanozolol,were identified among the 20 samples,disconsistent with labels on the package.Conclusion The LC-HRMS method is simple in pretreatment,sensitive and suitable for the detection of anabolic agents in tablet,capsule and injec-tion samples in the fields of anti-doping and judicial identification.

The advent of bruton tyrosine kinase inhibitors (BTKi) has offered more therapeutic choices for patients with B-cell malignancies. However, with its widespread application in recent years, the use of BTKi increases the risk of severe infections in patients. Here, we report three cases of B-cell malignancies, including one case of chronic lymphocytic leukemia and two cases of diffuse large B-cell lymphoma. During treatment with BTKi zanubrutinib, different degrees of invasive fungal disease (IFD) of the central nervous system occurred in these patients. All patients fully recovered following antifungal therapy. With a median follow-up of 35 months, all patients remained in a continuous remission state, and none of them had a recurrence of IFD.